Find information on thousands of medical conditions and prescription drugs.

Retrolental fibroplasia

Retinopathy of prematurity (ROP), also known as retrolental fibroplasia (RLF), is a disease of the eye that affects prematurely born babies. It is thought to be caused by disorganised growth of retinal blood vessels resulting in scarring and retinal detachment. more...

Home
Diseases
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
Gastroesophageal reflux...
Rabies
Radiophobia
Rasmussen's encephalitis
Raynaud's phenomenon
Reactive arthritis
Reactive hypoglycemia
Reflex sympathetic...
Regional enteritis
Reiter's Syndrome
Renal agenesis
Renal artery stenosis
Renal calculi
Renal cell carcinoma
Renal cell carcinoma
Renal cell carcinoma
Renal failure
Renal osteodystrophy
Renal tubular acidosis
Repetitive strain injury
Respiratory acidosis
Restless legs syndrome
Retinitis pigmentosa
Retinoblastoma
Retinoschisis
Retrolental fibroplasia
Retroperitoneal fibrosis
Rett syndrome
Reye's syndrome
Rh disease
Rhabdomyolysis
Rhabdomyosarcoma
Rheumatic fever
Rheumatism
Rheumatoid arthritis
Rickets
Rift Valley fever
Ringworm
Rocky Mountain spotted fever
Romano-Ward syndrome
Roseola infantum
Rubella
Rubeola
Rubinstein-Taybi syndrome
Rumination disorder
S
T
U
V
W
X
Y
Z
Medicines

ROP can be mild and may resolve spontaneously, but may lead to blindness in serious cases. Oxygen toxicity may contribute to the development of ROP.

International Classification of Retinopathy of Prematurity (ICROP)

The system used for described the findings of ROP is entitled, The International Classification of Retinopathy of Prematurity (ICROP). ICROP "demarcated the location of the disease into zones (1, 2, and 3) of the retina, the extent of the disease based on the clock hours (1-12), and the severity of the disease into stages (0-5)" .

Symptoms and prognosis

In preterm infants, the retina is often not fully formed. ROP occurs when abnormal tissue forms between the central and peripheral retina. There are 5 progressive stages to ROP. Stage 1 is mild and may resolve on its own without severe vision loss; stage 5 is severe and usually results in retinal detachment.

Multiple factors can determine how fast a patient progresses through the stages, including overall health, birth weight, the stage of ROP at initial diagnosis, and the presence or absence of "plus" disease. "Plus" disease occurs when the abnormal vessels in the retina invade other areas of the eye, greatly increasing the risk of retinal detachment.

The abnormal vessel growth often subsides spontaneously, but can progress to retinal detachment and vision loss in patients with extremely low birth weight. Patients with ROP are at greater risk for glaucoma, cataracts and myopia later in life, and should be examined yearly to help prevent and treat these conditions.

Treatment

  • Cryotherapy
  • "Indirect laser"
  • scleral buckle and/or vitrectomy may be considered for severe ROP with retinal detachment

Read more at Wikipedia.org


[List your site here Free!]


Nausea and Vomiting of Pregnancy
From OB/GYN News, 8/1/01 by Gerald G. Briggs

Because nausea and vomiting of pregnancy peaks at about 8 weeks, right in the middle of organogenesis, some physicians worry about prescribing drugs to pregnant women, including those that have been shown to be safe in pregnancy.

In my opinion, all the antiemetic drugs can be used in pregnancy with the exception of corticosteroids and marijuana, as their benefits outweigh their risks.

I consider the combination of the antihistamine/anticholinergic doxylamine and pyridoxine (vitamin [B.sub.6]) to be the firstline pharmacologic treatment of nausea and vomiting of pregnancy (NVP). These were the components of Bendectin, which was withdrawn by the manufacturer from the U.S. market in 1983 because of adverse publicity and litigation surrounding allegations that it was as sociated with limb reduction defects in babies exposed in utero. But in 1999, thc Food and Drug Administration deter mined that it was not withdrawn for safety reasons and added the combination back to its list of approved drug products that are considered safe and effective.

Bendectin is probably the most thoroughly studied drug combination in human pregnancy Among the estimated 30 million pregnant women who took Bendectin, no increase in or clustering of birth defects were detected.

Until this combination is available again in the United States, NVP can be treated with doxylamine, the over-the-counter nighttime sleep aid marketed as Unisom. One half of a 25-mg Unisom tablet can be taken with 25 mg of vitamin [B.sub.6] once or twice a day (Bendectin contained 10 mg of doxylamine and 10 mg of vitamin [B.sub.6] and was a slow-release formulation.)

Other antihistamines are also generally safe during pregnancy Still, all antihistamines should be avoided if premature labor occurs because, of a possible association between retrolental fibroplasia in premature babies exposed to antihistamines within 2 weeks of birth.

If intravenous therapy is necessary diphenhydramine (Benadryl) is the 'parenteral drug of choice. It is safe during pregnancy, although neonatal withdrawal has been reported with chronic use. Diphenhydramine also interacts with temazepam (Restoril), and has oxytocic properties when administered intravenously near term.

Oral dimenhydrinate (Dramamine) has been used extensively for NVP in Canada but not in this country Like diphenhydramine, it is safe during pregnancy but is tied to oxytocic effects when given intravenously near term.

Other antiemetics that can be used are dopamine antagonists. Phenothiazines, butyrophenones, and metoclopramide (Reglan) have the most direct effect on blocking the pathway between the center in the medulla that controls vomiting and the chemoreceptor trigger. zone. The drawback of dopamine antagonists is their dystonic effects. Prochiorperazine (Compazine) is also safe and effective during pregnancy and is probably one of the more common agents used by physicians for NVP. Like other phenothiazines, this drug also causes dystonic reactions, even 'with a single dose, but, has the advantage of being available in oral, rectal, intramuscular, and intravenous formulations.

The butyrophenone derivative droperidol is the most potent m this 'class nd is the most effective drug available for severe NVP and hyperemesis gravidarum. It is not an animal teratogen, and we have not seen anyclustering of or increase in birth defects. An. advantage is that the type of extrapyramidal side effects seen with droperidol tends to be akathisia, 'which is common, but I have never seen a dystonic reaction.

Our protocol for hyperemesis gravidarum' includes treatment with intravenous droperidol and intravenous diphenhydramine, which usually elicits a quick response. We use this combination because' droperidol is an effective antiemetic, and diphenhydramine is an effective antiemetic and an antidote for akathisia. After 2 days, we discharge patients on oral metoclopramide and hydroxyzine (Vistaril) four times a day

Metoclopramide has been safe and effective for NVP in numerous studies but is no more effectiverhan any other NVP drug. Hydroxyzine is another antihistamine alternative to doxylamine-pyridoxine.

The selective serotonin receptor antagonists dolasetron (Anzemet), granisetron (Kytril), and ondansetron (Zofran) don't appear to be human teratogens, but most have not been studied for NVP. They also are expensive and do not' offer any advantage over other drugs. Herbal medicines are also used for NVP but except for ginger, no 'data exist on their effectiveness, and 'safety data are lacking.

GERALD C. BRIGGS, B.Pharm., is pharmacist clinical specialist, Women's Hospital, Long Beach. Memorial Medical Center; clinical professor of pharmacy, University of California, San Francisco; and adjunct associate professor of pharmacy, University of Southern California, Los Angeles. He is also coauthor of the textbook "Drugs in Pregnancy and Lactation."

COPYRIGHT 2001 International Medical News Group
COPYRIGHT 2001 Gale Group

Return to Retrolental fibroplasia
Home Contact Resources Exchange Links ebay